Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination
Severe acute respiratory syndrome coronavirus 2 variants have continued to emerge in diverse geographic locations with a temporal distribution. The Lambda variant containing multiple mutations in the spike protein, has thus far appeared mainly in South America. The variant harbours two mutations in...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/22221751.2021.2008775 |
| _version_ | 1798014790719766528 |
|---|---|
| author | Meiyu Wang Li Zhang Qianqian Li Bo Wang Ziteng Liang Yeqing Sun Jianhui Nie Jiajing Wu Xiaodong Su Xiaowang Qu Yuhua Li Youchun Wang Weijin Huang |
| author_facet | Meiyu Wang Li Zhang Qianqian Li Bo Wang Ziteng Liang Yeqing Sun Jianhui Nie Jiajing Wu Xiaodong Su Xiaowang Qu Yuhua Li Youchun Wang Weijin Huang |
| author_sort | Meiyu Wang |
| collection | DOAJ |
| description | Severe acute respiratory syndrome coronavirus 2 variants have continued to emerge in diverse geographic locations with a temporal distribution. The Lambda variant containing multiple mutations in the spike protein, has thus far appeared mainly in South America. The variant harbours two mutations in the receptor binding domain, L452Q and F490S, which may change its infectivity and antigenicity to neutralizing antibodies. In this study, we constructed 10 pseudoviruses to study the Lambda variant and each individual amino acid mutation's effect on viral function, and used eight cell lines to study variant infectivity. In total, 12 monoclonal antibodies, 14 convalescent sera, and 23 immunized sera induced by mRNA vaccines, inactivated vaccine, and adenovirus type 5 vector vaccine were used to study the antigenicity of the Lambda variant. We found that compared with the D614G reference strain, Lambda demonstrated enhanced infectivity of Calu-3 and LLC-MK2 cells by 3.3-fold and 1.6-fold, respectively. Notably, the sensitivity of the Lambda variant to 5 of 12 neutralizing monoclonal antibodies, 9G11, AM180, R126, X593, and AbG3, was substantially diminished. Furthermore, convalescent- and vaccine-immunized sera showed on average 1.3–2.5-fold lower neutralizing titres against the Lambda variant. Single mutation analysis revealed that this reduction in neutralization was caused by L452Q and F490S mutations. Collectively, the reduced neutralization ability of the Lambda variant suggests that the efficacy of monoclonal antibodies and vaccines may be compromised during the current pandemic. |
| first_indexed | 2024-04-11T15:22:55Z |
| format | Article |
| id | doaj.art-dca44f6e3d4a4713ba1d3f31852b67fe |
| institution | Directory Open Access Journal |
| issn | 2222-1751 |
| language | English |
| last_indexed | 2024-04-11T15:22:55Z |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj.art-dca44f6e3d4a4713ba1d3f31852b67fe2022-12-22T04:16:19ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512022-12-01111182910.1080/22221751.2021.20087752008775Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccinationMeiyu Wang0Li Zhang1Qianqian Li2Bo Wang3Ziteng Liang4Yeqing Sun5Jianhui Nie6Jiajing Wu7Xiaodong Su8Xiaowang Qu9Yuhua Li10Youchun Wang11Weijin Huang12Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)Jiangsu Recbio Technology Co., Ltd.Peking University; State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking UniversityInstitute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)Peking University; State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking UniversityUniversity of South ChinaNational Institutes for Food and Drug ControlInstitute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)Severe acute respiratory syndrome coronavirus 2 variants have continued to emerge in diverse geographic locations with a temporal distribution. The Lambda variant containing multiple mutations in the spike protein, has thus far appeared mainly in South America. The variant harbours two mutations in the receptor binding domain, L452Q and F490S, which may change its infectivity and antigenicity to neutralizing antibodies. In this study, we constructed 10 pseudoviruses to study the Lambda variant and each individual amino acid mutation's effect on viral function, and used eight cell lines to study variant infectivity. In total, 12 monoclonal antibodies, 14 convalescent sera, and 23 immunized sera induced by mRNA vaccines, inactivated vaccine, and adenovirus type 5 vector vaccine were used to study the antigenicity of the Lambda variant. We found that compared with the D614G reference strain, Lambda demonstrated enhanced infectivity of Calu-3 and LLC-MK2 cells by 3.3-fold and 1.6-fold, respectively. Notably, the sensitivity of the Lambda variant to 5 of 12 neutralizing monoclonal antibodies, 9G11, AM180, R126, X593, and AbG3, was substantially diminished. Furthermore, convalescent- and vaccine-immunized sera showed on average 1.3–2.5-fold lower neutralizing titres against the Lambda variant. Single mutation analysis revealed that this reduction in neutralization was caused by L452Q and F490S mutations. Collectively, the reduced neutralization ability of the Lambda variant suggests that the efficacy of monoclonal antibodies and vaccines may be compromised during the current pandemic.http://dx.doi.org/10.1080/22221751.2021.2008775sars-cov-2lambda variantc.37neutralizationvaccinesconvalescent serummonoclonal antibodies |
| spellingShingle | Meiyu Wang Li Zhang Qianqian Li Bo Wang Ziteng Liang Yeqing Sun Jianhui Nie Jiajing Wu Xiaodong Su Xiaowang Qu Yuhua Li Youchun Wang Weijin Huang Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination Emerging Microbes and Infections sars-cov-2 lambda variant c.37 neutralization vaccines convalescent serum monoclonal antibodies |
| title | Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination |
| title_full | Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination |
| title_fullStr | Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination |
| title_full_unstemmed | Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination |
| title_short | Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination |
| title_sort | reduced sensitivity of the sars cov 2 lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination |
| topic | sars-cov-2 lambda variant c.37 neutralization vaccines convalescent serum monoclonal antibodies |
| url | http://dx.doi.org/10.1080/22221751.2021.2008775 |
| work_keys_str_mv | AT meiyuwang reducedsensitivityofthesarscov2lambdavarianttomonoclonalantibodiesandneutralizingantibodiesinducedbyinfectionandvaccination AT lizhang reducedsensitivityofthesarscov2lambdavarianttomonoclonalantibodiesandneutralizingantibodiesinducedbyinfectionandvaccination AT qianqianli reducedsensitivityofthesarscov2lambdavarianttomonoclonalantibodiesandneutralizingantibodiesinducedbyinfectionandvaccination AT bowang reducedsensitivityofthesarscov2lambdavarianttomonoclonalantibodiesandneutralizingantibodiesinducedbyinfectionandvaccination AT zitengliang reducedsensitivityofthesarscov2lambdavarianttomonoclonalantibodiesandneutralizingantibodiesinducedbyinfectionandvaccination AT yeqingsun reducedsensitivityofthesarscov2lambdavarianttomonoclonalantibodiesandneutralizingantibodiesinducedbyinfectionandvaccination AT jianhuinie reducedsensitivityofthesarscov2lambdavarianttomonoclonalantibodiesandneutralizingantibodiesinducedbyinfectionandvaccination AT jiajingwu reducedsensitivityofthesarscov2lambdavarianttomonoclonalantibodiesandneutralizingantibodiesinducedbyinfectionandvaccination AT xiaodongsu reducedsensitivityofthesarscov2lambdavarianttomonoclonalantibodiesandneutralizingantibodiesinducedbyinfectionandvaccination AT xiaowangqu reducedsensitivityofthesarscov2lambdavarianttomonoclonalantibodiesandneutralizingantibodiesinducedbyinfectionandvaccination AT yuhuali reducedsensitivityofthesarscov2lambdavarianttomonoclonalantibodiesandneutralizingantibodiesinducedbyinfectionandvaccination AT youchunwang reducedsensitivityofthesarscov2lambdavarianttomonoclonalantibodiesandneutralizingantibodiesinducedbyinfectionandvaccination AT weijinhuang reducedsensitivityofthesarscov2lambdavarianttomonoclonalantibodiesandneutralizingantibodiesinducedbyinfectionandvaccination |